Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes
Part of paid clinical trials in Glenview, Illinois.
- Sponsor
- Northwestern University
- Study ID
- NCT05898932
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Medical Management — OTHERParticipants will be managing condition with medication
- Surgical Management — OTHERParticipants will be managing condition with a surgery
Study Details
The goal of this project is to use newly developed patient-reported outcomes to improve the clinical care of patients with benign prostatic hyperplasia. The use of new patient-centered tools will improve evaluation and clinical decision-making by including symptoms not commonly measured in men, such as urinary incontinence, and allow for more frequent assessment of lower urinary tract symptoms through remote surveillance. Through the use of care-coordination checklists, clinicians can be more responsive to post-treatment symptom changes, resulting in reduced bother from lower urinary tract symptoms and higher quality of life in patients with benign prostatic hyperplasia.
Key Dates
- Start date
- Jun 1, 2023
- Status verified
- May 2025
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2026
Study Design
- Enrollment
- 300 participants (estimated)
Arms
- Arm: Medical ManagementParticipants will be managing condition with medication
- Arm: Surgical ManagementParticipants will be managing condition with a surgery
Primary Outcome Measure
Patient rating of global change [ Time Frame: Through study completion, from week 4 to week 24 ]
Central Contacts
- Dacey Maglaque847-503-4278
- Pooja Talaty847-503-4280
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NorthShore University HealthSystem Research Institute | Glenview | Illinois | 60026 | Alexander P. Glaser, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Glenview, IL
Related Studies
- A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia SymptomsRecruiting · Rivermark Medical · Bakersfield, California
- Emsella for Reducing tSUI After HOLEPNot Yet Recruiting · Northwestern University · Chicago, Illinois
- Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled TrialRecruiting · Northwestern University · Chicago, Illinois
- 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI TherapyRecruiting · Beth Israel Deaconess Medical Center · Boston, Massachusetts